Theranostic barcoded nanoparticles for personalized cancer medicine

Nature Communications

Volumn 7, Issue , 2016, Pages

  Yaari, Zvi ^a   Da Silva, Dana ^a   Zinger, Assaf ^a   Goldman, Evgeniya ^a   Kajal, Ashima ^a   Tshuva, Rafi ^a   Barak, Efrat ^a   Dahan, Nitsan ^a   Hershkovitz, Dov ^b   Goldfeder, Mor ^a   Roitman, Janna Shainsky ^a   Schroeder, Avi ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOUBLE STRANDED DNA; DOXORUBICIN; DRUG LOADED BARCODED LIPOSOME; GEMCITABINE; LIPOSOME; NANOPARTICLE; PLACEBO; SYNTHETIC DNA; UNCLASSIFIED DRUG; DNA; DRUG CARRIER;

CANCER; CELLS AND CELL COMPONENTS; DISEASE TREATMENT; DRUG; NANOPARTICLE; NANOTECHNOLOGY; RODENT; TUMOR; VIABILITY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CELL SUSPENSION; CELL VIABILITY; CONTROLLED STUDY; DNA BARCODING; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; FEMALE; MOUSE; NONHUMAN; PERSONALIZED MEDICINE; PREDICTION; SINGLE DRUG DOSE; THERANOSTIC NANOMEDICINE; TRIPLE NEGATIVE BREAST CANCER; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; GENETICS; HUMAN; KAPLAN MEIER METHOD; NEOPLASM; NUCLEOTIDE SEQUENCE; PROCEDURES; TUMOR CELL LINE; ULTRASTRUCTURE;

MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CELL LINE, TUMOR; DNA; DRUG CARRIERS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MICE, INBRED BALB C; NANOPARTICLES; NEOPLASMS; PRECISION MEDICINE; THERANOSTIC NANOMEDICINE; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84994831683     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms13325     Document Type: Article

References (58)

1. Symmans, W. F. et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J. Clin. Oncol. 25, 4414-4422 (2007).
2. Thomas, E. et al. The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial. J. Clin. Oncol. 22, 2294-2302 (2004).
3. Buzdar, A. U. et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J. Clin. Oncol. 17, 3412-3417 (1999).
4. Roxbury, D. et al. Hyperspectral microscopy of near-infrared fluorescence enables 17-chirality carbon nanotube imaging. Sci. Rep. 5, 14167 (2015).
5. Sotiriou, C., Piccart, M. J. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat. Rev. Cancer. 7, 545-553 (2007).
6. van't Veer, L. J., Bernards, R. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 452, 564-570 (2008).
7. Abelson, S., Shamai, Y., Berger, L., Skorecki, K., Tzukerman, M. Nichedependent gene expression profile of intratumoral heterogeneous ovarian cancer stem cell populations. PLoS ONE 8, e83651 (2013).
8. van de Wetering, M. et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 161, 933-945 (2015).
9. Cortazar, P., Johnson, B. E. Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer. J. Clin. Oncol. 17, 1625-1631 (1999).
10. Burstein, H. J. et al. American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays. J. Clin. Oncol. 29, 3328-3330 (2011).
11. Torchilin, V. P. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat. Rev. Drug Discov. 13, 813-827 (2014).
12. Stark, W. J. Nanoparticles in biological systems. Angew. Chem. Int. Ed. 50, 1242-1258 (2011).
13. Peer, D. et al. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2, 751-760 (2007).
14. Lammers, T., Aime, S., Hennink, W. E., Storm, G., Kiessling, F. Theranostic nanomedicine. Acc. Chem. Res. 44, 1029-1038 (2011).
15. Khandare, J., Calderon, M., Dagia, N. M., Haag, R. Multifunctional dendritic polymers in nanomedicine: opportunities and challenges. Chem. Soc. Rev. 41, 2824-2848 (2012).
16. Theek, B., Rizzo, L. Y., Ehling, J., Kiessling, F., Lammers, T. The theranostic path to personalized nanomedicine. Clin. Transl. Imaging 2, 66-76 (2014).
17. Miller, K., Erez, R., Segal, E., Shabat, D., Satchi-Fainaro, R. Targeting bone metastases with a bispecific anticancer and antiangiogenic polymeralendronate-taxane conjugate. Angew. Chem. Int. Ed. 48, 2949-2954 (2009).
18. Peer, D. Immunotoxicity derived from manipulating leukocytes with lipidbased nanoparticles. Adv. Drug Deliv. Rev. 64, 1738-1748 (2012).
19. Carmeliet, P., Jain, R. K. Angiogenesis in cancer and other diseases. Nature 407, 249-257 (2000).
20. Matsumura, Y., Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46, 6387-6392 (1986).
21. Schroeder, A. et al. Treating metastatic cancer with nanotechnology. Nat. Rev. Cancer 12, 39-50 (2012).
22. Harries, M., Ellis, P., Harper, P. Nanoparticle albumin-bound paclitaxel for metastatic breast cancer. J. Clin. Oncol. 23, 7768-7771 (2005).
23. Gibson, J. M., Alzghari, S., Ahn, C., Trantham, H., La-Beck, N. M. The role of pegylated liposomal doxorubicin in ovarian cancer: a meta-analysis of randomized clinical trials. Oncologist 18, 1022-1031 (2013).
24. Pisano, C. et al. Clinical trials with pegylated liposomal Doxorubicin in the treatment of ovarian cancer. J. Drug Deliv. 2013, 898146 (2013).
25. Mundra, V., Li, W., Mahato, R. I. Nanoparticle-mediated drug delivery for treating melanoma. Nanomedicine (Lond) 10, 2613-2633 (2015).
26. Chen, Y., Bathula, S. R., Yang, Q., Huang, L. Targeted nanoparticles deliver siRNA to melanoma. J. Invest. Dermatol. 130, 2790-2798 (2010).
27. Udhrain, A., Skubitz, K. M., Northfelt, D. W. Pegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma. Int. J. Nanomed. 2, 345-352 (2007).
28. Cooley, T. et al. A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi's sarcoma. Oncologist 12, 114-123 (2007).
29. Wong, A. D., Ye, M., Ulmschneider, M. B., Searson, P. C. Quantitative analysis of the enhanced permeation and retention (EPR) effect. PLoS ONE 10, e0123461 (2015).
30. Abaza, Y. M., Alemany, C. Nanoparticle albumin-bound-Paclitaxel in the treatment of metastatic urethral adenocarcinoma: the significance of molecular profiling and targeted therapy. Case Rep. Urol. 2014, 489686 (2014).
31. Jain, R. K., Stylianopoulos, T. Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol. 7, 653-664 (2010).
32. Elbaz, J., Willner, I. DNA origami: nanorobots grab cellular control. Nat. Mater. 11, 276-277 (2012).
33. Douglas, S. M. et al. Self-assembly of DNA into nanoscale three-dimensional shapes. Nature 459, 414-418 (2009).
34. Bettegowda, C. et al. Detection of circulating tumor DNA in early-and latestage human malignancies. Sci. Transl. Med. 6, 224ra224 (2014).
35. Brakmann, S. DNA-based barcodes, nanoparticles, nanostructures for the ultrasensitive detection and quantification of proteins. Angew. Chem. Int. Ed. 43, 5730-5734 (2004).
36. Condon, A. Designed DNA molecules: principles and applications of molecular nanotechnology. Nat. Rev. Genet. 7, 565-575 (2006).
37. Giljohann, D. A., Mirkin, C. A. Drivers of biodiagnostic development. Nature 462, 461-464 (2009).
38. Goluch, E. D. et al. A bio-barcode assay for on-chip attomolar-sensitivity protein detection. Lab Chip 6, 1293-1299 (2006).
39. Brakmann, S. DNA-based barcodes, nanoparticles, nanostructures for the ultrasensitive detection and quantification of proteins. Angew. Chem. Int. Ed. 43, 5730-5734 (2004).
40. Fan, R. et al. Integrated barcode chips for rapid, multiplexed analysis of proteins in microliter quantities of blood. Nat. Biotechnol. 26, 1373-1378 (2008).
41. Amir, Y. et al. Universal computing by DNA origami robots in a living animal. Nat. Nanotechnol. 9, 353-357 (2014).
42. Span, L. F. et al. The dynamic process of apoptosis analyzed by flow cytometry using Annexin-V/propidium iodide and a modified in situ end labeling technique. Cytometry 47, 24-31 (2002).
43. Freedman, N. D., Park, Y., Abnet, C. C., Hollenbeck, A. R., Sinha, R. Association of coffee drinking with total and cause-specific mortality. N. Engl. J. Med. 366, 1891-1904 (2012).
44. Isakoff, S. J. Triple-negative breast cancer: role of specific chemotherapy agents. Cancer J. 16, 53-61 (2010).
45. Vaidyanathan, G. Redefining clinical trials: the age of personalized medicine. Cell 148, 1079-1080 (2012).
46. Ng, P. C., Murray, S. S., Levy, S., Venter, J. C. An agenda for personalized medicine. Nature 461, 724-726 (2009).
47. Winkeljohn, D. L. Triple-negative breast cancer. Clin. J. Oncol. Nurs. 12, 861-863 (2008).
48. de Ruijter, T. C., Veeck, J., de Hoon, J. P., van Engeland, M., Tjan-Heijnen, V. C. Characteristics of triple-negative breast cancer. J. Cancer Res. Clin. Oncol. 137, 183-192 (2011).
49. Joensuu, H., Gligorov, J. Adjuvant treatments for triple-negative breast cancers. Ann. Oncol. 23(Suppl 6): vi40-vi45 (2012).
50. Shastry, M., Yardley, D. A. Updates in the treatment of basal/triple-negative breast cancer. Curr. Opin. Obstet. Gynecol. 25, 40-48 (2013).
51. Carlson, R. W. et al. NCCN practice guidelines for breast cancer. Oncology (Williston Park) 14, 33-49 (2000).
52. NCCN. Guidelines for patients, Stage IV breast cancer (Version 1. 2014). https://www. nccn. org/patients/guidelines/stage-iv-breast/index. html.
53. Haran, G., Cohen, R., Bar, L. K., Barenholz, Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim. Biophys. Acta 1151, 201-215 (1993).
54. Peleg-Shulman, T., Gibson, D., Cohen, R., Abra, R., Barenholz, Y. Characterization of sterically stabilized cisplatin liposomes by nuclear magnetic resonance. Biochim. Biophys. Acta 1510, 278-291 (2001).
55. Bligh, E. G., Dyer, W. J. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37, 911-917 (1959).
56. Riccardi, C., Nicoletti, I. Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat. Protoc. 1, 1458-1461 (2006).
57. Sidow, A., Spies, N. Concepts in solid tumor evolution. Trends Genet. 31, 208-214 (2015).
58. Sottoriva, A. et al. A Big Bang model of human colorectal tumor growth. Nat. Genet. 47, 209-216 (2015).